Two-year real-world outcome data from a single tertiary centre shows reduced ustekinumab persistence in a non-bio-naïve Crohn's disease cohort with penetrating disease, -ostomies and sarcopenia

• Main Authors: Saskia Inniss (Author), Konstantinos C. Fragkos (Author), Lisa Whitley (Author), Rachel Wimpory (Author), Eleanor Rebello (Author), Ana Lisboa (Author), Tanvi Khetan (Author), Jasmine Hassan (Author), Kate Simpson (Author), Anisha Bhagwanani (Author), Roser Vega (Author), Ioanna Parisi (Author), Paul Harrow (Author), Edward Seward (Author), Sara McCartney (Author), Stuart Bloom (Author), Andrew M. Smith (Author), Andrew Plumb (Author), Farooq Z. Rahman (Author)
• Format: Book
• Published: SAGE Publishing, 2023-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Ustekinumab was approved in 2016 for the treatment of moderate-severe Crohn's disease (CD). Clinical trials and real-world studies have suggested ustekinumab to be a safe and effective treatment; however, studies to date infrequently use imaging techniques to predict response to bio...